PROCEPT BioRobotics Securities Fraud Class Action
Analysis based on 6 articles · First reported Aug 28, 2026 · Last updated Sep 02, 2026
The disclosure of excess inventory and the subsequent securities class action have severely impacted PROCEPT BioRobotics' stock, which declined over 48% from August 2025 to February 2026. The lawsuit and ongoing investigation may lead to further financial and reputational damage, potentially affecting the company's ability to raise capital and its market valuation.
Hagens Berman filed a securities class action against PROCEPT BioRobotics Corporation (NASDAQ: PRCT) on behalf of investors who purchased PROCEPT common stock between February 28, 2024 and February 25, 2026. The lawsuit alleges that PROCEPT and other defendants violated federal securities laws by withholding information about its handpiece sales practices. Specifically, PROCEPT allegedly used an extensive bulk order discount program to incentivize customers to place orders exceeding their procedure demands, pulling forward sales and artificially inflating reported unit sales and revenues. The truth emerged through a series of disclosures: on August 6, 2025, Q2 2025 results showed handpiece sales missing consensus estimates; on November 4, 2025, Q3 2025 results again missed expectations and management slashed annual handpiece sales guidance; and on February 25, 2026, Q4 2025 results revealed that U.S. handpiece sales had exceeded procedures each quarter since Q1 2023, with cumulative excess customer inventory over 10,000 units and a 30% sequential decline in U.S. handpiece sales. Management also announced elimination of the bulk order discount program. As a result, PROCEPT shares declined by $22.06, or over 48%, from August 6, 2025 to February 25, 2026. The lead plaintiff deadline is September 22, 2026.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard